Company intelligence / Profile preview

Rhoshan Pharmaceuticals

Chadds Ford, Pennsylvania, United Statessalary.com ↗

Ownership: Private
Employees: ~50
Development stage: NDA

Overview

Rhoshan Pharmaceuticals is developing RHO-11, an injectable aspirin formulation focused on early treatment of heart disease and stroke. FDA approval was expected in 2023 according to older information.

Therapeutic areas: CardiovascularNeurology
Modalities: Small moleculesinjectable formulations of oral drugs
Industry: Biotech

Drug pipeline

1 asset

acetylsalicylic acid

NDA

Indications: Acute coronary syndrome

Beyond the preview

Go deeper on Rhoshan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhoshan Pharmaceuticals.

Explore the full profile